An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

PHASE2TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 13, 2016

Primary Completion Date

November 22, 2018

Study Completion Date

November 22, 2018

Conditions
Duchenne Muscular Dystrophy
Interventions
BIOLOGICAL

PF-06252616

Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002

Trial Locations (47)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

16147

UOC Farmacia - Istituto Gianna Gaslini,, Genova

UOC Medicina Fisica Riabilitativa - Istituto G. Gaslini, Genova

UOC Neurologia Pediatrica e Malattie Muscolari Istituto Gianna Gaslini, Genova

UOC Radiologia - Istituto Gianna Gaslini,, Genova

UOS Dipartimentale Endocrinologia Clinica Sperimentale - Ist., Genova

19104

Children's Hospital of Philadelphia, Philadelphia

21205

Kennedy Krieger Institute Out-patient Center, Baltimore

Kennedy Krieger Institute, Baltimore

21287

Johns Hopkins Hospital, Baltimore

Johns Hopkins Investigational Drug Service, Baltimore

27705

Duke University Medical Center, Lenox Baker Children's Hospital, Durham

27710

Duke University, Investigational Drug Pharmacy, Durham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

52242

University of Iowa ICTS, Clinical Research Unit, Iowa City

55454

University of Minnesota Masonic Children's Hospital, Minneapolis

55455

(For Drug deliveries) IDS Pharmacy, Minneapolis

63110

St. Louis Childrens's Hospital, St Louis

84108

Center for Clinical and Translational Sciences, Salt Lake City

Utah Center for Advanced Imaging and Research (UCAIR), Salt Lake City

84112

Investigational Drug Services, Salt Lake City

Utah Program for Inherited Neuromuscular Disorder, Salt Lake City

84132

University of Utah Hospital, Salt Lake City

University of Utah School of Medicine, Salt Lake City

90095

David Geffen School of Medicine at UCLA/UCLA Neurology, Los Angeles

Ronald Reagan UCLA Medical Center, Los Angeles

Ronald Reagan UCLA Pharmacy, Los Angeles

UCLA (David Geffen School of Medicine), Department of Orthopedic Surgery, Los Angeles

UCLA Clinical & Translational Research Center, Los Angeles

95817

University of California, Davis Medical Center, Sacramento

02114

Massachusetts General Hospital, Boston

T3B 6A8

Alberta Children's Hospital, Calgary

V6H 3V4

UBC Children's and Women's Health Centre of British Columbia, Vancouver

N6A5W9

Children's Hospital- London Health Sciences Centre, London

H1T 1C9

Centre de Readaptation Marie Enfant (CRME), Montreal

H3T 1C5

CHU Sainte-Justine, Montreal

00150

Dipartimento Pediatrico Universitario-Ospedaliero Endocrinologia, Rome

00165

Farmacia Ospedaliera, IRCCS Ospedale Pediatrico Bambino Gesu, Rome

IRCCS Ospedale Pediatrico Bambino Gesu - Centro Trials, Rome

U.O. Malattie Neuromuscolari e Neurodegenerative, IRCCS Ospedale Pediatrico Bambino Gesu, Rome

663-8501

Hyogo college of medicine hospital, Nishinomiya-shi

187-8551

National Center of Neurology and Psychiatry, Kodaira

WC1N 3JH

Dubowitz Neuromuscular Centre, Institute of Child Health, London

Great Ormond Street Hospital, London

NE1 3BZ

Institute of Genetic Medicine,Muscle Team, Newcastle upon Tyne

NE1 4LP

Clinical Research Facility, Newcastle upon Tyne

Royal Victoria Infirmary Research Pharmacy, Newcastle upon Tyne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02907619 - An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter